Skip to content

Methadone Dose Monitoring With a Remote Medication Monitor

Assessment of Methadone Dose Taken

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06837571
Enrollment
30
Registered
2025-02-20
Start date
2025-04-26
Completion date
2025-06-30
Last updated
2025-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Metabolism, Poor, CYP2D6-Related, Metabolism Medication Toxicity, Methadone Overdose, Methadone Toxicity, Pain, Chronic

Keywords

Pharmacokinetics

Brief summary

Proof of concept: Pilot Study A Pilot, proof of concept, observational study with a long-term goal to develop a minimally invasive wearable Remote Medication Monitor (RMM) that provides continuous, real-time data on methadone levels in interstitial fluid (ISF). An RMM could be used as a medication adherence monitor and would allow for the physician, counselor, patient, or family member to remotely verify that a physician-prescribed dose has been taken.

Detailed description

The investigator will conduct a non-randomized, non-blinded, feasibility study at a single center in the United States. The study will include up to 20 subjects of an equal number of male and female adults (ages 18-70) who have a prescription for methadone. In Aim 1, the investigators will determine if an RMM can continuously assess the status of taking a prescribed dose of methadone over time, by inserting the dermal ISF sensing elements into the subjects' abdominal skin. Biosample collections (i.e., ISF, blood) and pharmacokinetic monitoring will occur over a 6-hour period. By completing this aim, the investigator will determine if a physician is able to recognize the pharmacokinetic profile of a taken dose of methadone. The physician will see a dosing curve display generated from dermal ISF dialysis fluid sampling using an external fiberoptic sensor system that is worn continuously on the abdomen similar to continuous glucose monitors.

Interventions

Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Aptamer based Assay

Measurement of Methadone and its metabolites in ISF with LC-MS and RMM

Up to 15 minute periods of continuous ISF collection for analysis

Sponsors

Cari Health Inc.
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-70 * A prescription for methadone at a dose of 10mg or more for at least one week. * Taking methadone as prescribed during the last 4 days before consent to participate in the study.

Exclusion criteria

* Age \<18 or \>70 * A condition preventing or complicating ISF collection * dermatological (skin) condition * immunodeficiency * recent blood donation * anemia * end stage renal disease * liver cirrhosis * cancer * congestive heart failure * bleeding diathesis * tuberculosis (TB) * Any active severe depression * suicidal ideation * mania symptoms * Pregnancy * Intending to become pregnant during the course of the study * Enrolled in a substance use disorder treatment program * Under a conservatorship.

Design outcomes

Primary

MeasureTime frameDescription
Methadone Concentration in ISF before and after a dose1 daymeasure dermal interstitial fluid with LC-MS for methadone before and after a daily dose
Methadone Concentration in blood before and after a dose1 daymeasure blood for methadone with LC-MS before and after a daily dose
Concentration of Methadone in ISF with LC-MS versus Fluorescent Aptamer Switch2 daysmeasure ISF with two procedures (Liquid Chromatography - Mass Spectroscopy and Fluoroscopy
Concentration of Methadone in blood with LC-MS versus Fluorescent Aptamer Switch2 daysmeasure blood with two procedures (Liquid Chromatography - Mass Spectroscopy and Fluoroscopy
Pearson Correlation of Methadone between ISF and Blood2 daysmeasure blood and ISF methadone with LC-MS and determine pearson correlation
Pearson Correlation between Fluoroscopy and LC-MS ISF Methadone2 daysmeasure ISF for methadone by LC-MS and Fluoroscopy and determine Pearson correlation

Countries

United States

Contacts

Primary ContactFoster P Carr, MD
drcarr@carihealth.com6192343725

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026